# Cancer Cell Biology (CCB) Research Program

> **NIH NIH P30** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $52,560

## Abstract

PROJECT SUMMARY/ABSTRACT
The Cancer Cell Biology Program (CCB) personalizes cancer therapy by i) elucidating signaling and metabolic
networks controlling key cancer cell functions, ii) employing cutting-edge chemical biology and biologics to target
rate-limiting pathways in cancer, and iii) translating these insights to the clinic as improved therapies or
biomarkers that more accurately predict patient response. We address key cancer problems in our catchment
area, facilitated by biannual meetings with the Community Outreach and Engagement Core and our designated
CCB Liaison. Particular emphasis is placed on melanoma, and lung, pancreas, triple negative breast, and
prostate cancer, reflecting major catchment area burdens and disparities. Research is organized around three
complementary thematic aims: Aim 1: Identify regulatory mechanisms for key cancer-relevant genes that confer
selective dependencies in human tumors, Aim 2: Delineate how metabolism is reprogrammed in cancer and
discover targetable metabolic vulnerabilities, and Aim 3: Use structural, chemical, protein engineering, and
pharmacologic approaches to target cancer cell dependencies for therapeutic benefit. CCB is under tripartite
leadership by Richard Possemato, PhD (Basic), Alec Kimmelman, MD, PhD (Translational), and Vamsidhar
Velcheit, MD (Clinical). Our 53 Members and 14 Associate Members hail from 12 Departments at NYU Grossman
School of Medicine, the NYU Department of Chemistry, and the NYU College of Dentistry. CCB Members have
$24.2M in cancer-related funding (41% increase), including $8.3M in NCI grants (32% increase). Members are
highly productive and collaborative, publishing 806 peer-reviewed papers in high-impact journals (36% with
IF>10, 19% IF>15), with 16% intra-programmatic, 36% inter-programmatic, and 42% inter-institutional
publications during the current funding period. We filed 41 patents (19 licensed), had 26 patents issued (7
licensed), and created 5 biotechnology companies. Most importantly, CCB members made seminal findings with
clinical impact, including identifying novel signaling networks or metabolic dependencies. CCB houses the
Perlmutter Cancer Center (PCC) Biologics Initiative, which produced antibodies licensed to BioPharma and in
clinical trials or late-stage pre-clinical development. Multiple CCB discoveries have advanced along the
translational pipeline, including into clinical trials that are, or will soon be, open at PCC. CCB clinical investigators
also led 15 IITs, 4 ISTs, and multi-site trials and totaled 3,548 accruals, a dramatic increase driven by recruitment
of additional clinical trialists.

## Key facts

- **NIH application ID:** 10769317
- **Project number:** 2P30CA016087-43
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Richard Lewis Possemato
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $52,560
- **Award type:** 2
- **Project period:** 1996-12-01 → 2029-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10769317

## Citation

> US National Institutes of Health, RePORTER application 10769317, Cancer Cell Biology (CCB) Research Program (2P30CA016087-43). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10769317. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*